6533b85ffe1ef96bd12c1b6d

RESEARCH PRODUCT

A novel ultradeformable liposomes of Naringin for anti-inflammatory therapy

Amparo Ruiz SauríMaría Pleguezuelos-villaSilvia Mir-palomoAmparo NácherM.a. Ofelia Vila BusoOctavio Díez-sales

subject

0301 basic medicineAnti-Inflammatory AgentsDermatitis02 engineering and technologyPharmacologyMicechemistry.chemical_compoundColloid and Surface ChemistryZeta potentialSkinLiposomeTransdermal penetrationPellSurfaces and InterfacesGeneral Medicine021001 nanoscience & nanotechnologyFlavanonesPhosphatidylcholinesTetradecanoylphorbol AcetateBetamethasoneFemale0210 nano-technologyFlavanoneBiotechnologymedicine.drugAntiinflamatorisCell Survivalmedicine.drug_classDrug CompoundingSkin AbsorptionAdministration CutaneousIn vivo studiesAnti-inflammatory03 medical and health sciencesIn vivomedicineAnimalsPhysical and Theoretical ChemistryNaringinUltradeformable liposomesPhosphatidylethanolaminesLysophosphatidylcholinesFibroblastsIn vitro030104 developmental biologychemistryLiposomesNIH 3T3 CellsAnti-inflammatoryNaringin

description

[EN] Ultradeformable liposomes were formulated using naringin (NA), a flavanone glycoside, at different concentrations (3, 6 and 9 mg/mL). Nanovesicles were small size (similar to 100 nm), regardless of the NA concentration used, and monodisperse (PI<0.30). All formulations showed a high entrapment efficiency (similar to 88%) and a highly negative zeta potential (around -30 mV). The selected formulations were highly biocompatible as confirmed by in vitro studies using 3T3 fibroblasts. In vitro assay showed that the amounts (%) of NA accumulated in the epidermis (similar to 10%) could explain the anti-inflammatory properties of ultradeformable liposomes. In vivo studies confirmed the higher effectiveness of ultradeformable liposomes respect to betamethasone cream and NA dispersion in reducing skin inflammation in mice. Overall, it can conclude that NA ultradeformable liposomes can be considered as a promising formulation for the treatment of skin inflammatory diseases. (C) 2017 Elsevier B.V. All rights reserved.

10.1016/j.colsurfb.2017.11.068https://dx.doi.org/10.1016/j.colsurfb.2017.11.068